Adverse Events of Biologics in Severe Asthma

Abstract Purpose of Review To summarize current evidence on the immediate and long-term safety profile of the available monoclonal biological therapy (MBT) approved for the treatment of severe asthma. Recent Findings Clinical trials and real-world studies have shown that MBT are generally well tolerated, although certain adverse effects such as local reactions, anaphylaxis, parasitic or viral infections, malignancy, and cerebrovascular events are of special concern in these therapies or have already been reported. The frequency and severity of these effects vary depending on the specific agent and patient characteristics. Summary MBT have significantly improved the management of severe asthma, yet continuous monitoring of their safety profile remains essential to optimize long-term outcomes and minimize risks.